| Latest Forum Topics / Biosensors |
 Post Reply
|
|
Is Biosensors a good buy?
|
||||
|
bengster68
Master |
30-Aug-2008 11:09
|
|||
|
x 0
x 0 Alert Admin |
Stent Makers Getting Desperate |
|||
| Useful To Me Not Useful To Me | ||||
|
jackjames
Elite |
30-Aug-2008 00:27
|
|||
|
x 0
x 0 Alert Admin |
you are right.. i just read the Straits Times today, quite shock to read the full page of advert. confirmed result is good.... shit.. should have bought more today, heee.
|
|||
| Useful To Me Not Useful To Me | ||||
|
|
||||
|
bengster68
Master |
29-Aug-2008 23:07
|
|||
|
x 0
x 0 Alert Admin |
CORDIS – The CYPHER® Sirolimus-eluting Coronary Stent Outperforms the Taxus® Stent in People with Diabetes According to Clinical Data in the Journal of the American College of Cardiology August 28, 2008 – Warren, NJ – In patients with diabetes, the CYPHER® Sirolimus-eluting Coronary Stent outperformed the Taxus® Stent with significantly lower rates of in-segment restenosis (a reblockage within the stented area), target lesion revascularization (TLR; the need for another interventional procedure) and major adverse events (MACE, a composite of death, heart attack and TLR) at nine months according to clinical data appearing recently in the Journal of the American College of Cardiology. In this multi-center randomized clinical trial, the six month rate of in-segment restenosis was more than five times lower for the CYPHER® Stent compared to the Taxus® Stent (4.0 percent vs. 20.8 percent respectively (p<0.001). Most important for patients and physicians, key clinical outcomes measures were about four times lower for the CYPHER® Stent--at nine-months, clinically driven TLR for the CYPHER® Stent was 1.5 percent compared to 6.0 percent for the Taxus® Stent (p=0.032) while the composite clinical endpoint of MACE was 2.0 percent for the CYPHER® Stent compared to 8.0 percent for the Taxus® Stent (p=0.010). “These data provide interventional cardiologists with valuable new information about the use of drug-eluting stents in patients with diabetes, whose coronary artery disease presents such therapeutic challenges,” said Seong-Wook Park, M.D., PhD, F.A.C.C., and Principal Investigator of this trial. Dr. Park is from the Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea. Cordis has no financial relationship with Dr. Park. “The significant reduction in restenosis associated with the CYPHER® Stent, which translated to better outcomes for patients in terms of TLR and overall MACE, is impressive. It also is encouraging to note the data in this study on the safety of the CYPHER® Stent in this difficult-to-treat patient population,” Dr. Park continued. There was no difference between the two drug-eluting stents in the rates of death or myocardial infarction (heart attack). The rate of death was 0 percent for the CYPHER® Stent vs. 0.5 percent for the Taxus® Stent (p=0.999). The incidence of heart attack between the two groups was 0.5 percent (p=0.999). The study included a total of 400 patients divided evenly between the CYPHER® Stent and the Taxus® Stent (200 each) from five academic medical centers in Korea between May 2005 and March 2006. All patients had clinically defined diabetes. This study was supported by the Cardiovascular Research Foundation (Korea) and a grant from the Korean Ministry of Health and Welfare. “This study adds to the growing body of clinical evidence about the CYPHER® Stent in diabetics with coronary artery disease,” said Campbell Rogers, M.D., Chief Technology Officer, Cordis Corporation. “These data are consistent with other recently reported clinical trial data that clearly indicate that the CYPHER® Stent performs differently than the Taxus® Stent in diabetics, which has been a topic of discussion and debate within the medical community for some time.” The CYPHER® Stent does not have an approved indication for use in patients with diabetes in the United States. *** Cypher is never an easy DES to beat. Even Endeavor also cannot beat Cypher (except for potentially lesser late thrombosis cases due to better durable polymer technology). Next week LEADERS results, we will see how Biomatrix will perform against Cypher. Best Of The Best is really Buay Kan Tan man!!! BTW, Biomatrix is the perfect stent for diabetes patients. This was what i was told although i didn't research much into this. |
|||
| Useful To Me Not Useful To Me | ||||
|
investor
Senior |
29-Aug-2008 22:54
|
|||
|
x 0
x 0 Alert Admin |
The Biosensors Full page advert in the Straits Times surprised me very much. The mgmt team under the new CEO, Kleine is indeed quite different from the usually conservative Yoh Chi. The advert SIGNALS CONFIDENCE in the Leaders Trial results by using words like 'On 1st Sept, The world will find out ....' and 'The medical community will be watching and waiting to find out how Biosensors' REVOLUTIONARY drud eluting stent will perform against J&J's drug eluting stent...' This advertisement has up the ante that the Leaders clinical Trial should be very positive ! As usual, not a call to buy/sell.. Sometimes stocks can get sold down on news. (After the event). |
|||
| Useful To Me Not Useful To Me | ||||
|
jasonrxz
Senior |
29-Aug-2008 17:06
|
|||
|
x 0
x 0 Alert Admin |
close highest high.... good for BIG.... WE shall hold tight tight,... i will go buy the straits time and keep.... Think Bro bengster will get it frame up man... he is definately a BIG die hard fan... Salute to you!!! cheers 
|
|||
| Useful To Me Not Useful To Me | ||||
|
|
||||
|
idesa168
Elite |
29-Aug-2008 16:10
|
|||
|
x 1
x 0 Alert Admin |
Punters never dry up one lah! Tuesday punters are out, how about Wednesday's punter...hehehe!!! Anyway, contra players have T+5 for you info. Cheers!
|
|||
| Useful To Me Not Useful To Me | ||||
|
bengster68
Master |
29-Aug-2008 15:42
|
|||
|
x 0
x 0 Alert Admin |
Most likely contra punters getting out. Those who bought on Tuesday, at T+3 today must sell. These punters should be almost all out liao. |
|||
| Useful To Me Not Useful To Me | ||||
|
hopinj
Member |
29-Aug-2008 15:24
|
|||
|
x 0
x 0 Alert Admin |
why are ppl selling? when BIG could be releasing good news...who are sellers? contra players? |
|||
| Useful To Me Not Useful To Me | ||||
|
|
||||
|
bengster68
Master |
29-Aug-2008 14:30
|
|||
|
x 1
x 1 Alert Admin |
Sha  Sha Sha !!!
Sha Sha Sha !!!
Sha Sha Sha !!!
BIOSENSORS!!!!!!!!!!!!!!!!!!!!!!!!!! CHEEEEEEEEONG!!!!!!!!!!!!!!!!!! ARGGGGGHHHHHH!!!!!!!!!!!!!! |
|||
| Useful To Me Not Useful To Me | ||||
|
A02041315
Senior |
29-Aug-2008 14:20
|
|||
|
x 0
x 0 Alert Admin |
Last call for BIG!!!!!!!!!! Cheong!!!!!!!!!!!AR!!!!!!!!!!!!!!!!
|
|||
| Useful To Me Not Useful To Me | ||||
|
bengster68
Master |
29-Aug-2008 13:44
|
|||
|
x 0
x 0 Alert Admin |
Everybody still scared of disappointment from Biosensors? When it comes to clinical data, Biosensors sure Bo Bey Chao (no horse run). Cypher will be history next week. Taxus is already history liao. Just look at Taxus sales after Xience's clinical data came out. After everyone can see how poorly Taxus' clinical data is compared to Xience, Taxus sales dropped drastically from 45% to 27% market share since Jan 2008. Cypher sales dropped from 37% to 29% market share since Jan 2008. Xience sales within one month after USA launch is about 28%. Xience is expected to capture 41% market share by Dec 2008. After LEADERS trial, i believe JNJ's market share will plunge to below 20% in Oct 2008. People will also know that a relatively unknown Biosensors from Singapore can beat the shi.# out of Cypher and Cypher is actually no big deal after all (even if Endeavor cannot beat Cypher in Endeavor III RCT). I will tell you one of the biggest M&A joke around the DES industry. During the earlier days when BIG was just a small start-up and needed money to R&D Biomatrix, BIG transfered their older Everolimus DES technology "exclusively" to Guidant Corp after BIG discovered BiolimusA9 drug and want to commercailise this DES technology. BIG and Guidant signed a Everolimus DES technology transfer deal worth about US$0.1B cash. 2 years later, Abbott bought over entire Guidant's DES portfolio (which utilises BIG's older Everolimus DES technology) for US$4.1B cash. US$0.1B cash VS US$4.1B cash. Super suay and Lugi!!! But with that US$0.1B cash received from Guidant Corp is for an old technology that BIG wanted to discard anyway, BIG managed to R&D and commercial the Best Of The Best Biomatrix DES. Xience "Everolimus" DES will be the global DES market leader by end 2008. The one and only DES that can beat Xience is none other than Biomatrix. Absolutely no other stent can do it. Only BIG's latest BiolimusA9 DES technology can beat BIG's very own older Everolimus DES technology that they discarded to Guidant many years ago. BIG's discarded Everolimus DES technology is now going to be the global market leader. The MNC that want to be the next global DES market leader will have to buy over Biosensors. Absolutely no other way. Top class clinical data is everything for these medical device MNCs. Once they have it, sure to become market leader. Biosensors will be a hot DES takeover target after positive LEADERS results. |
|||
| Useful To Me Not Useful To Me | ||||
|
bengster68
Master |
29-Aug-2008 10:49
|
|||
|
x 0
x 0 Alert Admin |
**Interfair: BIOSENSORS IS TAKING THE LEAD IN DES CLINICAL EXCELLENCE ON 1ST SEPTEMBER, THE WORLD WILL FIND OUT HOW BIG's DES MEASURES UP AGAINST THE DES OFFERED BY J&J. SCORING MANY FIRSTS, THE BEST-IN-CLASS KNOWN AS LEADERS TRIAL IS THE FIRST HEAD-TO-HEAD RANDOMISED CLINICAL TRIAL COMPARING BIG's BIOLIMUS A9-ELUTING STENT WITH J&J's SIROLIMUS STENT. PRINCIPAL INVESTIGATOR PROF STEPHAN WINDECKER WILL REPORT THE FINDINGS INVOLVING 1700 REAL-WORLD PATIENTS RECRUITED FROM 10 LEADING MEDICAL INSTITUTIONS ACROSS EUROPE. THE MEDICAL COMMUNITY WILL BE WATCHING TO FIND OUT HOW BIG's REVOLUTIONARY DES WILL PERFORM AGAINST J&J's DES. **Bengster: This LEADERS trial is like the Olympics for DES. Biosensors' advertisement in Straits Times today is like calling for all Singaporeans supports to watch the match. If Singapore table-tennis team can beat China means Singapore paddlers are Best Of The Best liao. Confirm Gold Medal. Same for Biosensors VS JNJ. Maybe after LEADERS results Biosensors will put up another full page on Straits Times on the full details of the clinical data? Heng i told you guys got LEADERS and ESC coming up 2 weeks ago. Duno which fellow sold last week at 52.5cts. All eyes are on the results now...... Hope to see Singapore flag up!!! Wait for all the leading and most widely read medical journals in the world to publish LEADERS results. The news impact is going to be very huge. Unknown Singapore Company Biosensors Beat Global Stent Leader JNJ by Wide Margins In All End-Point Measurements In Massive Scale Real World Clinical Trial. Durable Polymer Drug Eluting Stents Are Obsolete. **Interfair: LEST SOME FORUMNERS NOT SURE WHY LEADERS IS NAMED LEADERS. IT IS BECAUSE LEADERS IS THE BEST-OF-THE BEST STENT AND KING OF DES. IT'S A GOLD MEDALIST IN THE DES INDUSTRY. **That means if JNJ is the DES King, Biosensors will be the King Of The King? Taxus is the "9,000 years Enunch Jiu Qian Shui", Endeavor and Xience are ambitious prince and crown-prince. I know Conor is definitely the "Joker". That makes JNJ the "King without wearing any clothes"??? JNJ's DES kingdom is going to be toppled over soon man!!! 
|
|||
| Useful To Me Not Useful To Me | ||||
|
|
||||
|
tanglinboy
Elite |
29-Aug-2008 10:41
Yells: "hello!" |
|||
|
x 0
x 0 Alert Admin |
I saw the advertisement too. They must be very confident of themselves. Let's see if its just hype or the real stuff.
|
|||
| Useful To Me Not Useful To Me | ||||
|
novena_33
Veteran |
29-Aug-2008 09:45
|
|||
|
x 0
x 0 Alert Admin |
they must have change the PR manager........ 
now Jack and Jill will have to pay premium...... |
|||
| Useful To Me Not Useful To Me | ||||
|
clauswu
Member |
29-Aug-2008 09:30
|
|||
|
x 0
x 0 Alert Admin |
Biosensors placed a full-page colour advertisement in today's Straits Times (Home section, page B27) announcing the presentation of the LEADERS results at ESC in Munich on Monday 1 Sep. Management muust be very confident that results will be positive. | |||
| Useful To Me Not Useful To Me | ||||
|
bengster68
Master |
29-Aug-2008 00:38
|
|||
|
x 0
x 0 Alert Admin |
Good stuff! US interventionalists shift to newer-generation DES despite lack of long-term evidence August 28, 2008 | Shelley Wood New York, NY - New York, NY - Within months of their approval, the two "next-generation" drug-eluting stents are increasingly eclipsing the Cypher and Taxus as the choice of interventionalists in the US. A survey of 41 "high-volume" interventional cardiologists conducted by JP Morgan estimates that within the first month of the Xience/Promus stent's launch, interventionalists are choosing it in 28% of cases, and they anticipate that its use will climb to 41% before the end of the year. (The Xience and Promus are identical stents, marketed separately by Abbott and Boston Scientific respectively, as part of the 2006 buyout deal.) By comparison, the survey suggests that Medtronic's Endeavor, on the market since February, is being used in 17% of cases, while Taxus stent use has declined to 27%, from 45% at the beginning of the year, and Cypher use is down to 29%, from 37% in early 2008. Survey respondents predicted that their use of both of these stents would continue to decline over the next few months. Interventionalists who spoke with heartwire acknowledged they are already developing new habits around stent choice, even in the absence of long-term data showing how the newer devices stack up against the Cypher and Taxus for safety and efficacy. "In our lab, we're seeing a complete disappearance of the Cypher and Taxus," Dr Ron Waksman (Washington Hospital Center, DC) told heartwire. "With the Taxus, I think it's because the results from SPIRIT III favored Xience over Taxus, and with the Cypher, it's a good stent, but it's first-generation and less deliverable." "Everybody is trying [the newer stents] out and taking them out for a spin," Dr David Cohen (Saint Luke's Mid America Heart Institute, Kansas City, MO), told heartwire. "They are the new darling, and most interventionalists, myself among them, tend to be somewhat enamored of and curious about the new thing. But the challenge for us with these types of devices is that the only thing you can really honestly evaluate is how they feel in your own hands, how they deliver, and how they look. No single person or single center has enough real experience with any of these new stents to make good strong conclusions about long-term performance and the things we really care about, like mortality or even restenosis." Gut instincts driving usage patterns According to Waksman, some interventionalists tend to view the Endeavor as "DES-lite," based on the higher angiographic late loss associated with the device in the clinical trials, but also believe it may carry less risk of stent thrombosis. So far, however, there are no clear signs that this stent will indeed be associated with higher rates of restenosis or that it is, indeed, a safer stent long-term. "People will say that in the cases when you're really worried about restenosis, you would stick to the Xience/Promus, Cypher, or Taxus, but if you're worried more about stent thrombosis or patient compliance with dual antiplatelet therapy, you would favor Endeavor; that's the tendency," Waksman said. "The perception is that the Endeavor still is the safer stent long-term, even though there are no definitive data." Indeed, both Drs Roxana Mehran and Jeffrey Moses (both at Columbia University, New York) acknowledged they lean toward the Endeavor in patients who are older, on warfarin, or who may need to interrupt dual antiplatelet therapy. "Certainly, when there is any issue about the antiplatelet use, I will go with an Endeavor stent. Those data seem very promising, although it's still not yet proven that it's much safer. It just seems to be looking that way," Mehran told heartwire. Moses, likewise, said he puts the Xience/Promus "in the Cypher/Taxus category as really a potent antirestenotic device," whereas the Endeavor, he acknowledged, "I use a little differently: I do believe that the late safety story emerging with Endeavor is pretty compelling, and, when the studies are done, I do not think we'll need the long-term dual antiplatelet therapy with this device." Not everyone agrees. Dr Stephen Ellis (Cleveland Clinic, OH) says Endeavor use there is in the "low single digits." "When you look at the available data . . . I don't think they have a compelling story to make them sound like they are necessarily better than any of the other DES," he said. "And that's the only reason to use that stent as far as I'm concerned." And Cohen points out that there is still another option. "Even with Endeavor, we don't have any data with less than six months of dual antiplatelet therapy, and what we're worried about is the people who are going to stop taking it in the first month or two, so I haven't tended to use Endeavor with that idea in mind," he said. "If I am really worried about compliance with dual antiplatelet therapy, I'll use a bare-metal stent." Dr Peter Berger (Geisinger Health System, Danville, PA) says the risk of late and very late stent thrombosis continues to be one of his chief concerns, and for that reason, he's "watching the Endeavor safety data closely. "I don't think we can be sure, and cross-trial comparisons are fraught with hazard, but there are at least some data to suggest Endeavor might possibly have a lower late thrombosis rate than other DES," he told heartwire. "It is also slightly easier to deliver than other DES, but to be honest, they all deliver well enough to make ease of delivery a nonissue in the overwhelming majority of cases." And even for the Xience/Promus, some interventionalists are taking a leap of faith. "At least in some people's minds, since the drugs are similar, they're substituting the Xience/Promus for Cypher directly," Ellis explained. "Others are more concerned about the lack of a robust long-term data set for safety and have not made that switch, and I tend to be in that camp." Almost everyone who spoke with heartwire praised the deliverability of the two new devices, compared with the Cypher and Taxus. "The stents that we've been using for the past five years were really frozen in time," Moses explained. "The bare-metal technology moved way ahead in terms of deliverability, so it's nice to have the combination of both back." Zealous reporting or new problems? But with deliverability comes a new set of issues and responsibilities. A review of the FDA's Manufacturer and User Facility Device Experience Database (MAUDE) indicates that of more than 100 adverse-event reports for the Endeavor stent between January 1 and July 31, 2008, more than half include reports of dislodgement with the stent. No adverse-event reports are yet posted for the Xience/Promus, since it was only recently approved. "We've heard of both Endeavor stents and Xience/Promus stents occasionally coming off the balloon, to a greater extent than one would expect based on our experience with the other stents. We've also, in our own lab, had some issues with the Xience sticking to the balloon—very reminiscent of the Taxus experience," Ellis said. "It may be a matter of overconfidence, or just that these stents are very deliverable and it may be a matter of trying to deliver them in situations in which you wouldn't even contemplate putting a Cypher, for example. So it's hard to know how much to blame the stent, the operator, or the expectations." Cohen, who said he had neither experienced nor heard anecdotally about stent dislodgement being a problem, said, "If it were occurring, I would probably chalk it up more to trying these stents in tougher lesions than we otherwise would than to any kind of manufacturing defects. Just like when Cypher first came out, people very zealously reported stent thromboses and those kinds of things." And Waksman, who said he knew of a few "anecdotal cases of dislodgement," said: "I don't think it's a problem; we haven't seen anything like this in our lab. I heard of one or two cases of dislodgement with Endeavor elsewhere, and I also heard of one or two cases where people couldn't retrieve the balloon with the Xience. But I wouldn't [put much stock] in these reports, because I think people are oversensitive to anything when it's new; if something significant had come up, we would have heard about it more vocally." Moses, who says he's not heard of any problems with either of the new stents, says he's "not aware of anyone really pushing these devices beyond where we were at the high-water mark with the previous versions." But he does point out that there are technical differences that require new skills or old skills to be remembered. "If you size these in a certain manner and then overdilate a very compliant balloon, there's a chance for edge dissection," he said by way of example. "That's nothing intrinsic to the device, it's how they're being used." Medtronic spokesperson Daniel Beach, asked about the dislodgement issue, emphasized that despite being used preferentially over Taxus and Cypher in difficult anatomies, "the dislodgement rate with Endeavor is very low, less than one hundredth of 1%." He also pointed out that device success and procedure success rates for Endeavor were superior to those of both Taxus and Cypher in randomized clinical trials. "All stents are affected by dislodgement at low rates; it is well understood by physicians and arises from the unavoidable need to force stents into difficult anatomies," he said. "The MAUDE database is a valuable resource but, as the FDA has publicly commented on several occasions, it should not be used to make device comparisons. This is particularly the case when looking at a newly available product and examples of a technology that are nearing the end of their lifecycle. For example, MAUDE takes no account of the possibility that one device is being used preferentially over another in challenging patients because of design and performance advantages. Such preferential usage could result in a disparity of adverse events associated with a particular device in MAUDE precisely because of its superior performance." Bare-metal stents still an option While Mehran, Moses, and colleagues at Columbia are world-famous for using DES in the majority of cases, other institutions are more conservative, producing an average DES usage in the US that hovers between 60% and 65%. Waksman says his lab is even more conservative, using just 50% DES. Key factors are the need for dual-antiplatelet therapy long-term, and in some cases, cost. Several interventionalists pointed out to heartwire that while the price for all four devices is slightly lower, the price wars that many had predicted with the advent of a fourth DES have not come to pass. Price and other factors that influence physician preferences may shift in the coming months with longer clinical-trial follow-up and registry data for the newer devices trickling in, as well as new study results comparing first- and next-generation DES. While Medtronic's 8800-patient PROTECT study and Abbott's SPIRIT IV and V trials are still under way or have yet to report results, the TCT 2008 meeting will include results from the smaller SORT-OUT III (Cypher vs Endeavor) and ZEST-AMI (Endeavor vs Cypher vs Taxus) studies. |
|||
| Useful To Me Not Useful To Me | ||||
|
jasonrxz
Senior |
28-Aug-2008 22:53
|
|||
|
x 0
x 0 Alert Admin |
Can B.I.G gap up tomolo morning??? Seems really alot of short term and long term player are holding tight on their shares for the great moment... With the rumours on the result and performance from D.J ( two days up liao) now, Can't see no reason that it stays at 60cts range.... Good support at 0.585 and if can chiong thru .62. It will go higher to 68 without much hinder... Let's again watch the show tomolo..... cheers.
|
|||
| Useful To Me Not Useful To Me | ||||
|
iPunter
Supreme |
28-Aug-2008 21:54
|
|||
|
x 0
x 0 Alert Admin |
Big boys or small boys... all only want to make money... |
|||
| Useful To Me Not Useful To Me | ||||
|
baseerahmed
Master |
28-Aug-2008 20:16
|
|||
|
x 0
x 0 Alert Admin |
( ... perhaps nothing new to ardent fans .. : ) )
|
|||
| Useful To Me Not Useful To Me | ||||
|
jasonrxz
Senior |
28-Aug-2008 18:21
|
|||
|
x 0
x 0 Alert Admin |
Well... Again mis read the movement and thought will continue to chiong today..... I believe that it's only taking a rest as profit taking from contra players and funds pulling are in action but still think BBs are holding on to the position. Tomolo will the big day before the announcement rite??? let see how BIG stocks moves and will take cue from there.. Very firm again that it will shoot northwards... Patience is the word.... So,, tighten up our seat belt and have a G force feeling by tomolo??? Cheers
|
|||
| Useful To Me Not Useful To Me | ||||
